Patents Assigned to Taiho Pharmaceutical Co., Inc.
  • Quinoline-substituted compound
    Patent number: 9650386
    Abstract: An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: May 16, 2017
    Assignee: Taiho Pharmaceutical Co., Inc.
    Inventors: Takao Uno, Katsumasa Nonoshita, Tadashi Shimamura